首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   282篇
  免费   19篇
  国内免费   1篇
儿科学   4篇
妇产科学   14篇
基础医学   17篇
临床医学   19篇
内科学   16篇
皮肤病学   1篇
神经病学   16篇
特种医学   93篇
外科学   33篇
预防医学   15篇
眼科学   1篇
药学   38篇
肿瘤学   35篇
  2022年   4篇
  2021年   4篇
  2020年   5篇
  2019年   9篇
  2018年   12篇
  2017年   8篇
  2016年   10篇
  2015年   12篇
  2014年   10篇
  2013年   17篇
  2012年   25篇
  2011年   27篇
  2010年   11篇
  2009年   11篇
  2008年   20篇
  2007年   24篇
  2006年   10篇
  2005年   19篇
  2004年   18篇
  2003年   9篇
  2002年   8篇
  2001年   2篇
  1998年   2篇
  1996年   2篇
  1995年   1篇
  1994年   1篇
  1993年   1篇
  1992年   3篇
  1990年   1篇
  1989年   2篇
  1988年   2篇
  1986年   3篇
  1985年   1篇
  1982年   2篇
  1978年   1篇
  1976年   1篇
  1972年   2篇
  1969年   1篇
  1962年   1篇
排序方式: 共有302条查询结果,搜索用时 0 毫秒
301.
Study Type – Prognosis (case series) Level of Evidence 4 What's known on the subject? and What does the study add? Nomograms are available that combine clinical and biopsy findings to predict the probability of pathologically insignificant prostate cancer in patients with clinically low‐risk disease. Based on data from patients with Gleason score 6, clinical stage ≤ T2a and PSA <20 ng/ml, our group developed the first nomogram models for predicting insignificant prostate cancer that incorporated clinical data, detailed biopsy data and findings from MRI or MRI/MRSI (BJU Int. 2007;99(4):786–93). When tested retrospectively, these MR models performed significantly better than standard clinical models with and without detailed biopsy data. We prospectively validated the previously published MR‐based nomogram models in a population of patients with Gleason score 6, clinical stage ≤ T2a and PSA <10 ng/ml. Based on data from this same population, we also developed two new models for predicting insignificant prostate cancer that combine MR findings and clinical data without detailed biopsy data. Upon initial testing, the new MR models performed significantly better than a clinical model lacking detailed biopsy data.

OBJECTIVES

  • ? To validate previously published nomograms for predicting insignificant prostate cancer (PCa) that incorporate clinical data, percentage of biopsy cores positive (%BC+) and magnetic resonance imaging (MRI) or MRI/MR spectroscopic imaging (MRSI) results.
  • ? We also designed new nomogram models incorporating magnetic resonance results and clinical data without detailed biopsy data. Nomograms for predicting insignificant PCa can help physicians counsel patients with clinically low‐risk disease who are choosing between active surveillance and definitive therapy.

PATIENTS AND METHODS

  • ? In total, 181 low‐risk PCa patients (clinical stage T1c–T2a, prostate‐specific antigen level <10 ng/mL, biopsy Gleason score of 6) had MRI/MRSI before surgery.
  • ? For MRI and MRI/MRSI, the probability of insignificant PCa was recorded prospectively and independently by two radiologists on a scale from 0 (definitely insignificant) to 3 (definitely significant PCa).
  • ? Insignificant PCa was defined on surgical pathology.
  • ? There were four models incorporating MRI or MRI/MRSI and clinical data with and without %BC+ that were compared with a base clinical model without %BC and a more comprehensive clinical model with %BC+. Prediction accuracy was assessed using areas under receiver–operator characteristic curves.

RESULTS

  • ? At pathology, 27% of patients had insignificant PCa, and the Gleason score was upgraded in 56.4% of patients.
  • ? For both readers, all magnetic resonance models performed significantly better than the base clinical model (P ≤ 0.05 for all) and similarly to the more comprehensive clinical model.

CONCLUSIONS

  • ? Existing models incorporating magnetic resonance data, clinical data and %BC+ for predicting the probability of insignificant PCa were validated.
  • ? All MR‐inclusive models performed significantly better than the base clinical model.
  相似文献   
302.

The aim of the study was to evaluate the performance of the Prophet forecasting procedure, part of the Facebook open-source Artificial Intelligence portfolio, for forecasting variations in radiological examination volumes. Daily CT and MRI examination volumes from our institution were extracted from the radiology information system (RIS) database. Data from January 1, 2015, to December 31, 2019, was used for training the Prophet algorithm, and data from January 2020 was used for validation. Algorithm performance was then evaluated prospectively in February and August 2020. Total error and mean error per day were evaluated, and computational time was logged using different Markov chain Monte Carlo (MCMC) samples. Data from 610,570 examinations were used for training; the majority were CTs (82.3%). During retrospective testing, prediction error was reduced from 19 to?<?1 per day in CT (total 589 to 17) and from 5 to?<?1 per day (total 144 to 27) in MRI by fine-tuning the Prophet procedure. Prospective prediction error in February was 11 per day in CT (9934 predicted, 9667 actual) and 1 per day in MRI (2484 predicted, 2457 actual) and was significantly better than manual weekly predictions (p?=?0.001). Inference with MCMC added no substantial improvements while vastly increasing computational time. Prophet accurately models weekly, seasonal, and overall trends paving the way for optimal resource allocation for radiology exam acquisition and interpretation.

  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号